Cite
HARVARD Citation
Roperch, J. et al. (2016). Promoter hypermethylation of HS3ST2, SEPTIN9 and SLIT2 combined with FGFR3 mutations as a sensitive/specific urinary assay for diagnosis and surveillance in patients with low or high-risk non-muscle-invasive bladder cancer. BMC cancer. 16 (1), pp. 1-9. [Online].